• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOCOMPATIBLES UK LTD THERASPHERE; YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOCOMPATIBLES UK LTD THERASPHERE; YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW Back to Search Results
Model Number 1.79GBQ
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Hemorrhage/Bleeding (1888)
Event Type  Injury  
Manufacturer Narrative
Btg medical assessment: on the (b)(6) 2019, patient was treated with 1.79gbq of therasphere administered in the left liver via femoral artery.Patient was hospitalised for digestive hemorrhage (start (b)(6) 2019, stop (b)(6) 2019) and has been treated by sandostatine, prophylactic antibiotherapy and elastic on oesophagus varices.Investigator listed causality of the sae as concurrent disease and confirmed the event not to be related to the administration procedure or therasphere® device action taken: surgery or interventional radiology procedure and concomitant medication.At baseline patient is to be classified bclc c, multifocal tumor and alteration of liver function.The event occurred 5 weeks after therasphere administration in a patient that has liver cirrhosis.It is likely that therasphere treatment has led to the increase of preexisting portal hypertension, and caused the upper gi hemorrhage it is of note that the patient received a treatment even the presence of "warning", child b8, elevated bilirubin, this patient was at high risk of disease decompensation.Hemorrhage is an anticipated adverse event listed in the study protocol/risk management documentation.Severity grade 4; serious: yes, patient was hospitalised; anticipated; related: device possibly increased pre existing portal hypertension.No device malfunction was reported and no corrective and preventive action (capa) plan has been identified.The lot number associated with the therasphere administration was not reported, therefore no investigation could be performed.If additional information becomes available, a follow up report will be submitted.No other information is available that could confirm/deny the alleged event.At this time this report is considered final.
 
Event Description
Auto-notification received from datatrak site # (b)(4), subject number: 250015-002, (b)(6) 2019.Subject number: 250015-002 male patient born in 1956, (b)(6).Main comorbidities; alcohol intake history and tobacco intake history.Disease characteristics: liver cirrhosis related to alcohol.Tumour type: hcc diagnosed (b)(6) 2017, multifocal tumour in the right and left liver.Patient has received prior anti-cancer treatments, loco regional liver treatment and liver surgery.The loco regional liver treatment has been listed as ablation: not document i if it was rfa, microwave, or cryo.The patient required liver resection and the liver segment that was removed.Pre treatment biology: bilirubin 44 micro mol/l, albumin 27gr/l, asl 3xuln child pugh score b8, bclcc and ecog not measured, on the (b)(6) 2019, patient was treated with 1.79gbq of therasphere administered in the left liver via femoral artery.Patient was hospitalised for digestive hemorrhage (start (b)(6) 2019, stop (b)(6) 2019) and has been treated by sandostatine, prophylactic antibiotherapy and elastic on oesophagus varices.Investigator listed causality of the sae as concurrent disease and confirmed the event not to be related to the administration procedure or therasphere® device action taken: surgery or interventional radiology procedure and concomitant medication.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
THERASPHERE
Type of Device
YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW
Manufacturer (Section D)
BIOCOMPATIBLES UK LTD
chapman house farnham bus park
weydon lane
farnham, GU9 8 QL
UK  GU9 8QL
Manufacturer (Section G)
BIOCOMPATIBLES UK
chapman house
weydon lane
farnham, GU9 8 QL
UK   GU9 8QL
Manufacturer Contact
sandra bausback-aballo
300 four falls corporate cente
300 conshohocken state road
west conshohocken,, PA 19428-2998
6103311537
MDR Report Key9238695
MDR Text Key167155502
Report Number3002124543-2019-00062
Device Sequence Number1
Product Code NAW
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
H980006
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,s
Reporter Occupation Physician
Type of Report Initial
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/25/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number1.79GBQ
Device Catalogue NumberN/A
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received09/25/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
Patient Age63 YR
-
-